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Is the six-minute walk test correlated with disease control and
quality of life in children with asthma?
Hasan YÜKSEL1, Özge YILMAZ1, Bülent GÖKŞEN2, Senem ÜSTÜN2, Ayhan SÖĞÜT1

Aim: To evaluate the changes in a 6-min walk test (6MWT) and quality of life (QoL) before and after asthma control
is achieved in children. A 6MWT is used in the determination of disease severity in many chronic childhood diseases.
Materials and methods: Thirty-six asthmatic children, aged 6 to 15 years, were enrolled before asthma control was
achieved. Disease severity parameters during the previous 3 months were recorded. All of the children completed an
asthma control questionnaire (ACQ) and received a symptom score; a 6MWT was performed during enrollment and 1
month later, when asthma control was achieved.
Results: The initial and follow-up mean 6MWT distances were 500.2 ± 139.1 and 577.8 ± 147.9 m, respectively (P <
0.001). The 6MWT distances and ACQ scores were significantly correlated initially (rho = –0.35, P = 0.04). The 6MWT
distance was not correlated with clinical parameters (P > 0.05 for all). The initial ACQ score was significantly correlated
with the symptom score and duration of asthma (rho = 0.62 vs. rho = –0.37).
Conclusion: A 6MWT may be used in the functional assessment of children with uncontrolled asthma; it correlates
with ACQ scores. The absence of a correlation between the 6MWT and patient-reported symptom severity or other
clinical parameters may indicate the necessity to include a functional assessment into the clinical evaluation as well as
QoL measures.
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Introduction
The 6-min walk test (6MWT) is a performance-based
test to assess exercise tolerance over time that has been
shown to be valid and reproducible in many different
cardiopulmonary disease states (1-4). In adults with
chronic obstructive pulmonary disease, it has been
shown to correlate with morbidity and mortality, and
in children with cystic fibrosis, it has been reported
to correlate with some clinical parameters (5,6).
Moreover, 6MWT results were determined to be lower
in children with chronic disease states as compared
to healthy peers (7). Therefore, the acceptability of
the 6MWT has also been demonstrated in children
(7,8). It measures the responses of all of the systems

during exercise but does not provide information
on each system involved in exercise tolerance (9).
It is reported to evaluate the submaximal level of
exercise capacity, since patients determine the pace
rate themselves, but since most daily activities are
performed at a submaximal exercise capacity, it
is reported to reflect the daily functional state of
the patient (9). The test has also been shown to be
valid for use in functional capacity assessment in ill
children (10). Exercise capacity is the most common
functional deterioration in children with asthma.
This deterioration in exercise capacity is expected to
influence the quality of life (QoL). Therefore, exercise
capacity may be used as a functional parameter in the
determination of asthma control status.
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The new concept of asthma treatment both in
children and adults focuses on “control” and QoL
measures, which are important patient-reported
outcome measures that provide rational ways to
determine asthma control (11,12). One of these
questionnaires, an asthma control questionnaire
that was developed by Juniper et al., aims to measure
the adequacy of asthma control (13). Therefore, it
is essential to combine the functional and clinical
parameters of disease control with patient-reported
outcomes.
The aims of this study were to evaluate the changes
in the 6MWT and QoL before and after asthma
control was achieved in children and to assess the
correlation among the 6MWT distance, asthma
control questionnaire (ACQ) score, and patientreported disease severity score.
Materials and methods
Subjects
Included in the study were 36 children (17 male, 19
female), aged 6-15 years, who had moderate asthma
and clinical findings of uncontrolled asthma. Diagnosis
of asthma was based on a history of recurrent cough
and wheezing with prolonged expiration time, which
demonstrated clinical reversibility with short-acting
bronchodilator therapy by a beta-2 agonist (11).
Study design
At the beginning of the study, all of the children
enrolled were asked to fill out the ACQ and symptom
score forms. Moreover, they were asked about the
number of acute asthma symptom episodes, days
of hospitalizations, days of bronchodilator use, and
systemic requirement during the previous 3 months.
After all of the information was gathered, a 6MWT
was performed by all of the participants. One month
after asthma control was achieved, when the patient
was clinically stable and lacking acute asthma
symptoms, the ACQ was filled out again and another
6MWT was performed.
The study was approved by the institutional
ethics committee and written informed consent was
obtained from the children and their parents before
enrollment in the study.
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Six-minute walk test
A 6MWT was performed according to the guidelines
of the American Thoracic Society (9). The patients
were tested in a 20-m-long quiet and empty hallway
and the same hallway was used for all of the 6MWTs,
considering that the layout of the track can influence
the results (5). The patients were allowed to rest for
10 min before the test was initiated. They were then
instructed to walk at a pace that they could tolerate,
and it was explained that the aim of the test was to
measure the maximal distance that they could walk
in the 6-min time period. The test was self-paced
and the children were allowed to rest if they could
not tolerate the walking, but the time continued to
run. Vital parameters including pulse rate and blood
pressure were measured before and after the test. The
tests were performed under the supervision of one
of the pediatricians in the study. The pediatrician
instructed the child to start walking at the beginning
of the test. He informed the patient of each minute
that passed and counted each lap that the patient
finished.
Asthma control questionnaire
The ACQ, developed by Juniper et al., aims to assess
the adequacy of asthma control and is composed of
7 questions (13). Of the questions, 5 are about the
symptoms of asthma during the previous 7 days and 1
is about inhaled bronchodilator use during the same
time period. The last question is about predicted
forced expiratory volume in 1 s (FEV1)%, which is
assessed by clinical staff. However, because this study
included children aged 6-15 years, and since most of
the children did not cooperate with the spirometry
adequately, this last question was not assessed in our
study. It has been shown that shortened versions of
the ACQ, omitting the FEV1 question, were also
valid in clinical trials (14).
Patient-reported asthma symptom score
The asthma symptom score that was used in this
study included 6 items reflecting chronic asthma
symptoms, such as dyspnea, tightness in the chest,
daytime wheeze, nocturnal wheeze, and daily
performance during the previous 3-month period
(15). Scoring of the items increases from 0 to 3 as the
severity increases. The total score is expressed as the
sum of all of the scores of the items.
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Statistical analyses were performed using SPSS 13.0
(SPSS, Chicago, IL, USA). Nonparametric tests
were used in the analysis because the values were
widely distributed both for the 6MWT and ACQ
results. The Wilcoxon signed-rank test was used to
compare the 6MWT and ACQ results before and
after the achievement of asthma control. Spearman’s
correlation analysis was performed to assess the
correlation among the ACQ results, symptom score,
and 6MWT distance. Moreover, correlations of other
disease severity parameters with the ACQ results,
symptom score, and 6MWT distance were performed
with Spearman’s correlation analysis.

walked after asthma control was achieved when
compared to the initial evaluation (P < 0.001) (Figure
1, Table 2).
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Results
Characteristics of the study population
The mean age of the children included in the study
was 9.8 years with a standard deviation of 2.6 years.
The mean duration of asthma was 5.1 ± 3.8 years.
During the previous 3-month period, the mean
days of inhaled bronchodilator usage and systemic
steroid requirements were 3.8 ± 4.8 and 1.3 ± 2.4,
respectively. The mean number of episodes of acute
asthma symptoms was 0.9 ± 0.9 and the mean
number of days of hospitalizations was 0.5 ± 1.3. The
mean asthma symptom score was 4.6 ± 2.9 during
acute asthma symptoms (Table 1).
6MWT before and after asthma control was
achieved
The mean distance of the 6MWT at the initial
evaluation was 500.2 ± 139.1 m, whereas after the
achievement of asthma control, it was 577.8 ± 147.9
m. There was a significant increase in the distance

Controlled

Figure 1. Distribution of the 6MWT results before and after the
achievement of asthma control.

ACQ scores before and after asthma control was
achieved
There was a significant decrease in the ACQ scores
after asthma control was achieved when compared
to the initial evaluation (1.6 ± 0.8 vs. 0.3 ± 0.5, P <
0.001) (Figure 2, Table 2).
Correlation of the ACQ, clinical parameters, and
6MWT
There was a significant correlation between the
6MWT distance and the ACQ score during the initial
evaluation (rho = –0.35, P = 0.04). However, the
6MWT distance was not significantly correlated with
any of the clinical parameters assessed, including
symptom score, bronchodilator and systemic steroid
requirement, number of episodes of acute asthma
findings, and days of hospitalizations during the

Table 1. Disease characteristics of the study subjects (n = 36).
Mean ± SD
Age (years)

9.8 ± 2.6

Duration of asthma (years)

5.1 ± 3.8

Asthma symptom score in the previous 3 months

4.6 ± 2.9

Days of bronchodilator requirement in the previous 3 months

3.8 ± 4.8

Days of systemic steroid requirement in the previous 3 months

1.3 ± 2.4

Number of acute asthma symptom episodes in the previous 3 months

0.9 ± 0.9

Days of hospitalization in the previous 3 months

0.5 ± 1.3
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Table 2. Mean ACQ and 6MWT results before and after the achievement of asthma control.

6MWT distance (m)
ACQ score

Uncontrolled

Controlled

P*

500.2 ± 139.1

577.8 ± 147.9

0.000

1.6 ± 0.8

0.3 ± 0.5

0.000

*Wilcoxon signed-rank test.

impaired in children with uncontrolled asthma.
Considering that childhood asthma is a reversible
condition with clinical assessment parameters
completely normal between exacerbations, these
parameters would be expected to improve with the
achievement of asthma control. Many previous
studies have evaluated the changes in 6MWT results
in children with chronic diseases including cystic
fibrosis; however, there are no studies that have
evaluated the change with asthma control (6,7).

3.5
p = 0.00
3.0
ACQ score

2.5
2.0
1.5
1.0
0.5
0.0
Uncontrolled

Controlled

Figure 2. Distribution of the ACQ scores before and after the
achievement of asthma control.

previous 3 months (rho = –0.13, –0.24, –0.13, –0.16,
and –0.19, respectively). Similarly, there was no
correlation between the age of the child or duration
of asthma and the 6MWT distance (rho = 0.33 and
rho = 0.26, respectively). On the other hand, the ACQ
score during the initial evaluation was significantly
correlated with the symptom score and duration of
asthma (rho = 0.62 vs. –0.37).
After asthma control was achieved, the correlation
of the 6MWT with the ACQ score was not significant
(rho = 0.01). There was no significant correlation
between the changes in the 6MWT distances and
the ACQ scores before and after the achievement of
asthma control (rho = 0.01).
Discussion
Current asthma treatment relies primarily on the
“control” concept (11). This includes functional
and clinical assessments as well as patient-reported
outcomes (12). A 6MWT is a reliable and valid tool
to assess the functional exercise tolerance of children,
and the ACQ is a valid tool to assess asthma control
(1,7,8,13,14). Both parameters are expected to be
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Changes in the 6MWT have been evaluated
in the treatment of different diseases, including
endothelin-1 antagonist therapy in pulmonary
hypertension cases, and the validity and reliability of
the test has been demonstrated (8,16). Uncontrolled
asthma would be expected to deteriorate functional
exercise tolerance. The results of our study indicated
a significant improvement in the 6MWT and QoL
scores of children after the achievement of asthma
control when compared to the initial values. This
result emphasizes the functional impairment
associated with uncontrolled asthma. Since the
functional status of the child is related to his or her
daily activities and interaction with friends, it would
be expected to influence the QoL.
The correlation of QoL with clinical parameters
has been assessed in many diseases with
contradictory results (1,4,16-19). In our study, the
6MWT distances and ACQ scores were significantly
correlated at the beginning of the study when the
children had uncontrolled asthma. This was similar
to the results of previous studies (1,4,16). In a study
on adult asthma patients, the ACQ scores and
2-min walking test results were shown to correlate
significantly (1). In another study on patients
with pulmonary hypertension, a correlation was
demonstrated between the 6MWT and QoL scores
(16). Additionally, the 6MWT results were found to
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be correlated with another QoL measure, the shortform 36 health survey, in patients discharged from
the hospital after acute respiratory distress syndrome
(4). Moreover, in patients with bronchiectasis, the
6MWT was found to be significantly correlated with
QoL scores but not with the extent of disease detected
by computerized tomography (20). On the contrary,
a significant correlation was detected between lung
function tests, QoL, and 6MWT results (19). All of
these results suggest that the 6MWT is significantly
correlated with QoL measures but not with other
clinical assessment parameters.
Although the 6MWT result and the ACQ score at
the initial evaluation were significantly correlated in
our study, the changes in these 2 outcome measures
were not correlated when retested after the acute
stage. This was similar to the results of a previous
study on patients with pulmonary hypertension
receiving endothelin-1 antagonist treatment, which
reported that 6MWT distances and QoL scores
were significantly correlated at all time points but
that the change in these 2 outcome measures were
not correlated (16). The lack of correlation between
the changes in the 6MWT distances and QoL scores
identifies that the QoL is not influenced only by
a state of physical well being but is also influenced
by many other aspects of an individual’s health
status, including psychosocial factors. The lack of
correlation between changes in the ACQ scores and
6MWT results might also be due to a threshold of
difference in functional measurements that existed
for the change to be noticed by the patients as an
improvement, as suggested in a previous study on
chronic obstructive pulmonary disease (COPD) (17).
Moreover, we did not detect a significant correlation
between the 6MWT distances and ACQ scores after
the achievement of asthma control. This was mostly
attributed to the ACQ scoring system, which yielded
0 in asymptomatic patients.
At the beginning of the study, the patient-reported
asthma severity score was significantly correlated
with the QoL score but not with the 6MWT
results. This finding, emphasizing that patientreported outcomes may not correlate completely
with functional outcome measures, is important
considering that the aim of recent asthma guidelines
are control-based asthma treatment, necessitating
the integration of both parameters in evaluation (11).

Previous research about the correlation of functional
performance-based exercise tolerance tests reported
conflicting results (1,8,21,22). A study performed on
adults with chronic obstructive disease or chronic
asthma,demonstrated a significant correlation
between the 6MWT results and perceived exertion
and breathlessness (21). This difference may be partly
explained by the different study populations: children
with moderate asthma and adults with chronic airway
obstruction or severe chronic asthma (21). Asthma in
children has completely reversible clinical findings,
whereas COPD and chronic severe asthma do not.
This might have led to differences in the perception
of patients of their symptoms. However, similar to
our study, research on adult asthmatics demonstrated
a significant correlation between the 6MWT results
and asthma severity scores with multivariate analysis
(1). Neither the asthma severity score nor the 6MWT
result was shown to be significantly correlated with
lung function test results in a group of patients with
cystic fibrosis (22). However, another study on adults
with cystic fibrosis demonstrated a correlation of the
6MWT distances with clinical parameters including
body weight and maximal expiratory pressure (8).
These different findings are important in emphasizing
that functional exercise capacity assessment provides
a different aspect of evaluation than either patientreported outcome measures or clinical assessment
parameters.
The limitations of this study include the relatively
low number of patients and the large range of ages.
However, age was not detected to be correlated with
the 6MWT results, and therefore it was not thought
to influence the results. Moreover, the addition
of a healthy control group would have aided in
comparisons. However, the aim of the study was to
compare the children with themselves during and
after acute asthma symptoms; therefore, a healthy
control group was not included.
In conclusion, the 6MWT may be used in the
functional assessment of children with uncontrolled
asthma, and the results of this test correlate well with
ACQ scores. Both evaluation measures improved
after asthma control was achieved. The absence
of a correlation between the 6MWT distance and
patient-reported symptom severity, as well as other
clinical disease severity parameters, may indicate the
necessity of including a functional assessment in the
clinical evaluation, as well as QoL measures.
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